In direct-compression immediate-release tablet manufacture, sodium starch glycollate pharma grade Type A functions through rapid intraparticle water uptake and particle swelling rather than through pH-dependent effervescence or ionic exchange. At a typical addition ratio of 2–8 % w/w, the disintegrant is introduced after the active pharmaceutical ingredient, filler and glidant have been pre-blended in a bin blender operating at 6–12 min⁻¹ for 10–20 min. The final lubricant addition of magnesium stearate is maintained at 0.5–1.0 % w/w with a mixing window of 2–5 min to avoid shear-induced hydrophobization of the sodium starch glycollate particle surface. Tablet compression is conducted on rotary presses with precompression force set between 2 kN and 5 kN, main compression force between 5 kN and 15 kN, and turret speeds of 20–80 rpm depending on tooling design. Compliance for the finished immediate-release tablet is verified against USP <701> disintegration, USP <711> dissolution, USP <905> uniformity of dosage units, and Ph. Eur. 2.9.1 disintegration when the market is European. Terminal finished product types include immediate-release tablets in the 100–500 mg total mass range, with fracture strength typically maintained between 40 N and 80 N. Rapid swell capacity is observable as viscosity onset in aqueous systems above 2 % w/v; however, the compressibility of sodium starch glycollate is poorer than that of microcrystalline cellulose, so tablet formulations requiring high mechanical strength should not exceed 6 % w/w without increasing the directly compressible filler ratio or adjusting press dwell time. Field-scale observations indicate that batch-to-batch variation in carboxymethyl substitution can shift the disintegration endpoint by 10–30 s when starch source lots differ, making identity testing by infrared absorption and sedimentation volume a routine release check under the USP-NF sodium starch glycollate monograph requirements.

How Does Intragranular SSG Exert the Wicking Threshold in Fast-Melt Compacts?

For orally disintegrating tablet formats prepared by direct compression, sodium starch glycollate pharma grade is typically incorporated intragranularly with mannitol or sorbitol as the dominant filler. Addition levels in this application cluster between 5 % w/w and 10 % w/w, because the requirement is not merely tablet breakup within a conventional 15-minute window but complete wetting and structural collapse under an internal target of 30–90 s using USP <701> or Ph. Eur. 2.9.1 immersion conditions. The production process for fast-melt compacts involves low-shear blending of sodium starch glycollate with a directly compressible polyol, an evaporative sweetener, and a glidant such as colloidal silicon dioxide at 0.25–0.75 % w/w. Compression is deliberately operated at reduced force, commonly 5–12 kN, to maintain tablet porosity above 25 %; tooling with deeply embossed punch faces and a high-speed rotary press equipped with forced feeder can produce edge capping if blend moisture falls below 1.0 %. The terminal finished product type is an orally disintegrating tablet of 50–350 mg mass with friability controlled below 1.0 % according to USP <1216> or an internally harmonized friability method. Because sodium starch glycollate swells in a pH-independent manner, it provides disintegrant function without the alkaline mouthfeel associated with effervescent salts; however, at use levels above 8 % w/w, residual starch-derived particulate matter can produce a slightly gritty mouthfeel after disintegration. Compliance for the excipient includes USP-NF sodium starch glycollate monograph tests for pH, sodium content, and loss on drying, together with ICH Q3D elemental impurity documentation for oral dosage forms. The operational boundary defined by residual moisture above 2.5 % is observed to reduce interparticle friction and increase sticking to low-hardness polyol blends on high-speed presses, and pre-drying of the polyol to 0.5–1.0 % loss on drying is therefore specified in line setup.

Following roller compaction at an apparent hydraulic pressure of 2–8 MPa, dry granulation lines frequently observe that intragranular sodium starch glycollate subjected to compaction pressure loses part of its rapid swelling response. The dry granulation process introduces the disintegrant either before compaction at 2–5 % w/w intragranularly or after milling at 1–3 % w/w extragranularly; the split addition is justified because the intragranular fraction contributes to granule porosity, while the extragranular fraction reacts immediately when the tableted compact contacts dissolution medium. Production equipment typically includes a roller compactor with side sealing and a milling system fitted with a 0.8–1.25 mm rasping screen. Terminal finished product types include tablets compressed from roller-compacted granules, where final tablet mass varies between 150 mg and 800 mg, and where disintegration endpoint is controlled by extragranular disintegrant distribution. Compliance to USP <701> disintegration and USP <905> uniformity of dosage units is supplemented by granule particle size analysis according to USP <786> or Ph. Eur. 2.9.12. Residual moisture of the granulated intermediate is typically kept at 1.5–2.5 % before final blending. When extragranular disintegrant is added after milling, a diffusion blender at 10–15 min⁻¹ for 10 min ensures distribution homogeneity; over-blending beyond 20 min can segregate the low-bulk-density sodium starch glycollate from densified granules. Published data for this specific configuration is limited with respect to the interaction between roll surface temperature and disintegrant glass transition, but production records show that sustained roller surface temperatures above 35 °C during long campaigns soften sodium starch glycollate particles and increase sticking to the compaction surface, requiring periodic water-cooled roller checks. At the final tablet stage, an additional extragranular disintegrant level above 3 % w/w is generally unnecessary because the wicking channels already established by the granular structure provide sufficient liquid entry; however, dense granulations with bulk density above 0.75 g/cm³ may require the upper end of the specified extragranular range to meet disintegration acceptance criteria.

Capsule Plug Disintegration and Moisture-Redistribution Variability

During automatic capsule filling, the powder plug is formed by a dosator or tamping pin with compression forces between 30 N and 120 N, and the cellulose or gelatin shell contributes moisture that can redistribute to the fill. Sodium starch glycollate pharma grade is used in hard shell capsule formulations at 2–8 % w/w to create plug erosion and swelling upon shell dissolution, particularly when the fill is composed of poorly soluble drugs, lactose, and dicalcium phosphate. The terminal finished product type includes hard gelatin and HPMC capsules with fill weights from 150 mg to 500 mg, where the disintegration acceptance criterion follows USP <701> or Ph. Eur. 2.9.1 without recourse to tablet hardness testing. The production process for powder-filled capsules involves pre-blending the disintegrant with the diluent portion for 5–10 min, adding the active ingredient, and then blending for an additional 10–15 min at 8–12 min⁻¹ in a V-blender or bin blender; magnesium stearate at 0.25–0.75 % w/w is introduced at the final lubrication step with a mixing time not exceeding 3 min. Moisture-mediated loss of function is less pronounced than with croscarmellose sodium, but gelatin capsule shells with moisture contents above 13 % can cause localized swelling of sodium starch glycollate particles at the plug-shell interface, producing a slower dissolution front in capsules stored at 40 °C/75 % RH for periods longer than 3 months. Compliance documentation for capsule applications references ICH Q1A stability conditions, USP <467> residual solvents where applicable, and FDA 21 CFR 211.110 in-process sampling of fill weight and plug height. Because the filling process creates a compacted plug rather than a compressed tablet, the extent of plug densification correlates with dissolution variability, and a plug porosity threshold below 20 % is associated with incomplete wetting and delayed release. The lower addition ratio of 2 % w/w is reserved for low-dose, high-solubility active ingredients, while the upper ratio of 8 % w/w is used only for poorly erodible plugs containing high levels of hydrophobic fillers; beyond that limit, powder flow is typically reduced because the moisture-affine particles increase interparticle cohesion in the hopper.

When an Intragranular–Extragranular Split Is Justified

High-shear wet granulation and fluid-bed granulation both impose mechanical and moisture stresses on sodium starch glycollate, which can reduce later swelling performance if the entire quantity is added before granulation. Wet granulation trials using a vertical high-shear mixer with impeller speeds of 200–500 min⁻¹ and a chopper speed of 1000–3000 min⁻¹ show that intragranular addition at 2–5 % w/w assists granule disintegration and liquid distribution during binder addition, while extragranular addition at 2–4 % w/w provides rapid final tablet disintegration. The terminal finished product type includes immediate-release tablets from wet granulated intermediates, with granule size after dry milling controlled through a 1.0–1.6 mm screen. Drying is conducted in a fluid-bed dryer at 50–60 °C until loss on drying reaches 1.5–2.5 %, because lower moisture levels increase granule friability and higher moisture levels can cause punch-face filming. Compliance for the wet granulated tablet is determined by USP <701>, USP <711>, and Ph. Eur. 2.9.1, with granulate particle size distribution monitored by sieve analysis according to USP <786> or Ph. Eur. 2.9.12. The operational boundary is set by the binder system: sodium starch glycollate is compatible with aqueous povidone and hypromellose binder solutions, but granulation fluids with pH above 10 and simultaneous drying temperatures above 55 °C should be avoided because the carboxymethyl starch structure can hydrolyze under prolonged alkaline heat. In fluid-bed granulation, inlet air temperature is often limited to 60–70 °C, and spray rate is adjusted to maintain product temperature below 35 °C to prevent premature swelling of the disintegrant in the wetted mass. Batch-to-batch variance in final disintegration time is more strongly influenced by the point of disintegrant addition than by absolute total disintegrant level; a total of 6 % w/w split as 2 % w/w intragranular and 4 % w/w extragranular consistently produces shorter disintegration than 6 % w/w all intragranular under the same compression force.

Sachet and dispersible granule formats incorporating sodium starch glycollate pharma grade are manufactured by dry blending, wet granulation, or extrusion-spheronization, with a typical disintegrant addition level of 2–6 % w/w of the final granule mass. Terminal finished product types include dispersible granules administered after suspension in water, granulate blends requiring fast sediment dispersion without effervescence as the primary release mechanism, and pediatric sachet granules with fill mass between 1 g and 5 g. The production process for sachet granules uses a fluid-bed granulator with top spray at a binder spray rate of 5–15 g/min per kg and inlet air temperature of 55–65 °C, followed by sieving through a 0.8–1.4 mm screen. Extragranular sodium starch glycollate is then added at 1–2 % w/w before filling into sachet packs, but the filling line must maintain relative humidity below 40 % to avoid particle bridging. Compliance for dispersible granules is evaluated against USP <701> for the dispersed liquid system, Ph. Eur. 2.9.1, and USP <905> for unit dose uniformity of the filled sachet. Because sodium starch glycollate is an insoluble swelling material rather than a soluble filler, the formulation must include a wetting agent or a high-solubility polyol to ensure that granules do not form a gel-like raft at the water surface. The operational limitation in sachet packaging is electrostatic charge build-up at low humidity, which can cause low-density disintegrant particles to adhere to aluminum foil surfaces and produce variable fill weights; equipment grounding and humidity-controlled filling suites at 40–50 % RH mitigate this effect. Published data for sodium starch glycollate use in injectable or parenteral sachet formats is limited, and the particulate nature of the excipient does not meet the clarity and sterility requirements of injectable finished products; therefore no injection application scenario is included.